Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

NCT05235516 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT05235516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05235516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Lead sponsor
Akeso
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 21, 2022
Completion date
May 31, 2029
Enrollment
636 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cervical carcinoma